Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer

Cells. 2020 Nov 17;9(11):2494. doi: 10.3390/cells9112494.

Abstract

The development of targeted therapies increases treatment options for metastatic castration resistant prostate cancer (mCRPC) patients. There is a need for strong predictive and prognostic signatures to guide physicians in treating mCRPC patients. In this review we unravel the possible actionability in the AR pathway, PI3K AKT signaling, and DNA repair pathways. Additionally, we make recommendations on biomarker trial design, and the clinical use of this new type of data.

Keywords: androgen receptor; biomarker; histology; mCRPC; prostate cancer; targeted therapies.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Biomarkers, Tumor / analysis*
  • Humans
  • Male
  • Neoplasm Metastasis / drug therapy
  • Neoplasm Metastasis / genetics*
  • Phosphatidylinositol 3-Kinases / drug effects
  • Phosphatidylinositol 3-Kinases / genetics
  • Prognosis
  • Prostatic Neoplasms, Castration-Resistant / diagnosis
  • Prostatic Neoplasms, Castration-Resistant / drug therapy*
  • Prostatic Neoplasms, Castration-Resistant / genetics
  • Receptors, Androgen / drug effects*
  • Receptors, Androgen / metabolism

Substances

  • Biomarkers, Tumor
  • Receptors, Androgen